Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies

OBJECTIVE: The present network meta-analysis (NMA) was conducted to summarize the direct and indirect evidence of common programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors including avelumab, atezolizumab, cemiplimab, nivolumab, and pembrolizumab for the treatment of no...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Maofen, Liu, Chunjiao, Ding, Dongxiao, Tian, Hui, Yu, Chaoqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127412/
https://www.ncbi.nlm.nih.gov/pubmed/35619899
http://dx.doi.org/10.3389/fonc.2022.827050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127412/
https://www.ncbi.nlm.nih.gov/pubmed/35619899
http://dx.doi.org/10.3389/fonc.2022.827050

Ejemplares similares